Cephalon to acquire Gemin X Pharma
Gemin X Pharma stockholders could also receive up to $300m in cash payments upon the achievement of certain regulatory and sales milestones. Gemin X Pharma is a privately-held
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.